Sutro Biopharma Inc（STRO）资讯与事件STROSutro Biopharma Inc

Sutro Q2 Revenue $9.84M, Below Consensus

Reports Q2 revenue $9.84M, consensus $11.04M. "During the second quarter, we continued to execute swiftly across our next-generation ADC portfolio, highlighted by encouraging early clinical data from our ongoing Phase 1 study of STRO-004, having rapidly enrolled our initial dose escalation cohorts in just seven months and now optimizing our go-forward dose," said Jane Chung, Sutro's Chief Executive Officer. "We have observed early clinical responses alongside favorable safety, tolerability, and a differentiated pharmacokinetic profile in patients with few remaining treatment options. The favorable tolerability profile and wider therapeutic index of our DAR8 exatecan ADC allows us to dose higher than other TF-targeting ADCs. These findings strengthen our confidence in STRO-004's potential to deliver meaningful clinical benefit and provide the opportunity to safely combine with other therapies, while further validating our proprietary ADC platform."

Sutro Q1 Revenue $14.52M, Exceeds Expectations

Reports Q1 revenue $14.52M, consensus $7.41M. "During the first quarter, we continued to execute across our clinical and preclinical portfolio, positioning Sutro for key data readouts later this year," said Jane Chung, Sutro's CEO. "Dose escalation is rapidly progressing in our Phase 1 trial of STRO-004, and we remain on track to report initial safety, pharmacokinetic and early activity data in mid-2026, which we believe will provide important insights into its clinical profile and our platform as a whole. This clinical momentum is reinforced by preclinical data we presented at the recent AACR Annual Meeting, which highlighted the robust and consistent antitumor activity of STRO-004, as well as continued progress across our broader ADC pipeline."

Sutro Biopharma Releases Promising Preclinical Data for STRO-004

Sutro Biopharma announced promising preclinical data across its pipeline of next- generation ADCs in five posters and one oral presentation at the American Association for Cancer Research, AACR, Annual Meeting 2026. Of note, results from a preclinical study of STRO-004, its DAR8 Topo1 ADC targeting Tissue Factor, were reviewed in an oral presentation titled "STRO-004, an exatecan-based next-generation tissue factor-targeted ADC, demonstrates superior efficacy across TF-expressing solid tumors in a comprehensive single-mouse PDX trial." In the preclinical study, STRO-004 demonstrated robust and consistent antitumor activity across a broad range of TF-expressing solid tumor patient-derived xenograft models, with improved efficacy compared to benchmark ADCs. At a single, clinically relevant dose of 5 mg/kg, STRO-004 achieved remarkable disease control and tumor reduction across multiple tumor types. STRO-004's favorable tolerability, with a highest non-severely toxic dose of 50 mg/kg, and pharmacokinetic profile are expected to enable increased drug exposure and payload delivery, supporting the Company's belief that STRO-004 will demonstrate superior depth and durability of response in the clinic.